Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors

Checkpoint inhibitors (CPI) represent a novel therapeutical strategy with a high efficacy both in solid and hematological cancers. They act by reactivating the immune system against neoplastic cells but may, in turn, cause immune-related adverse events (IRAEs) involving several organs with variable...

Descripción completa

Detalles Bibliográficos
Autores principales: Fattizzo, Bruno, Rampi, Nicolò, Barcellini, Wilma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143083/
https://www.ncbi.nlm.nih.gov/pubmed/35631383
http://dx.doi.org/10.3390/ph15050557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143083/
https://www.ncbi.nlm.nih.gov/pubmed/35631383
http://dx.doi.org/10.3390/ph15050557

Ejemplares similares